abrdn plc Takes $6.01 Million Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

abrdn plc purchased a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 552,572 shares of the biopharmaceutical company's stock, valued at approximately $6,006,000. abrdn plc owned about 1.01% of Marinus Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in MRNS. China Universal Asset Management Co. Ltd. boosted its position in Marinus Pharmaceuticals by 383.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 5,003 shares during the period. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the 4th quarter valued at approximately $134,000. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company's stock valued at $20,749,000 after purchasing an additional 31,233 shares during the period. Acuta Capital Partners LLC acquired a new position in Marinus Pharmaceuticals during the 3rd quarter valued at approximately $157,000. Finally, Adage Capital Partners GP L.L.C. boosted its position in Marinus Pharmaceuticals by 6.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company's stock valued at $23,381,000 after purchasing an additional 173,226 shares during the period. 98.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Truist Financial reduced their price objective on Marinus Pharmaceuticals from $25.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 17th. Oppenheimer restated a "market perform" rating and set a $9.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Robert W. Baird reiterated a "neutral" rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $16.07.

Marinus Pharmaceuticals Price Performance

MRNS stock traded down $0.01 during trading hours on Friday, hitting $1.41. 1,136,344 shares of the stock traded hands, compared to its average volume of 4,540,129. The stock has a 50-day simple moving average of $7.51 and a 200 day simple moving average of $8.15. Marinus Pharmaceuticals, Inc. has a one year low of $1.11 and a one year high of $11.26. The company has a market cap of $77.18 million, a P/E ratio of -0.53 and a beta of 0.91. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The firm had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. During the same period in the prior year, the business earned ($0.76) EPS. Equities analysts forecast that Marinus Pharmaceuticals, Inc. will post -2.23 earnings per share for the current year.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.